美国结石病患病率及手术趋势
基于美国商业保险与联邦医疗保险(Medicare)数据库的回顾性分析显示,2011至2019年间商业人群结石病患病率由1.04%小幅降至1.01%(P<0.0001),Medicare人群由1.84%升至2.34%(P<0.0001);两人群中输尿管镜(URS)与经皮肾镜取石术(PCNL)手术量增加,冲击波碎石(SWL)手术量减少。
要点
- 商业人群结石病患病率由1.04%降至1.01%(P<0.0001),Medicare人群由1.84%升至2.34%(P<0.0001)。
- 商业人群URS手术量增加22.6%(P<0.0001),Medicare人群增加56.6%(P<0.0001)。
- 商业人群PCNL手术量增加17.4%(P<0.0001),Medicare人群增加27.5%(P<0.0001);SWL手术量商业人群减少26.9%(P<0.0001),Medicare人群减少3.8%(无统计学显著性)。
核心结论
- 研究期间美国商业人群结石病患病率小幅下降,Medicare人群患病率上升。
- 两人群中URS和PCNL手术量均增加,SWL手术量均减少。
研究设计与样本
- 回顾性分析,分别使用Merative MarketScan商业数据库和Medicare标准分析文件(5%样本)。
- 纳入2011至2019年间在任何诊疗场所具有主要结石诊断或结石手术(URS、PCNL或SWL)的18岁及以上患者,分析在患者层面进行。
主要发现
- 商业人群结石病患病率由1.04%降至1.01%(P<0.0001);Medicare人群由1.84%升至2.34%(P<0.0001)。
- 商业人群URS手术量增加22.6%(P<0.0001),Medicare人群增加56.6%(P<0.0001)。
- 商业人群PCNL手术量增加17.4%(P<0.0001),Medicare人群增加27.5%(P<0.0001)。
- 商业人群SWL手术量减少26.9%(P<0.0001),Medicare人群减少3.8%(结果无统计学显著性)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the prevalence of stone disease and procedure trends among US commercial and Medicare populations. METHODS: Retrospective analyses for a US commercial population and Medicare population were conducted using the Merative MarketScan Commercial Database and Medicare Standard Analytic File (5% sample), respectively. Patients aged 18+ were included if they had an encounter in any setting with a primary stone diagnosis or stone procedure (ureteroscopy [URS], percutaneous nephrolithotomy (PCNL), or shockwave lithotripsy [SWL]) between 2011 and 2019. Analyses were conducted at the patient level. RESULTS: Over the study time horizon, the prevalence of stone disease showed a small yet statistically significant decrease in the commercial population (1.04%-1.01%; P.ß<.ß0.0001) and a statistically significant increase in the Medicare population (1.84%-2.34%; P.ß<.ß0.0001). URS.ßprocedure volumes increased by 22.6% (P.ß<.ß0.0001) in the commercial population and by 56.6% (P.ß<.ß0.0001) in the Medicare population over the study period. Similarly, PCNL.ßprocedure volumes increased by 17.4% (P.ß<.ß0.0001) in the commercial population and 27.5% (P.ß<.ß0.0001) in the Medicare population. Procedure volumes for SWL decreased by 26.9% in the commercial population (P.ß<.ß0.0001) and by 3.8% in the Medicare population although the results were not statistically significant. CONCLUSION: The prevalence of stone disease showed a small decrease in the US commercial population and an increase in the Medicare population over the study time horizon. In both populations, increasing procedure volumes were observed for URS and PCNL while decreasing volumes were observed for SWL.
引用
- Monga M, Murphy M, Paranjpe R, et al. Prevalence of Stone Disease and Procedure Trends in the United States. Urology. 2023. PMID: 37062518. doi:10.1016/j.urology.2023.03.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。